抗生素英文課件-Introduction-to-Antibacterial-Therapy_第1頁
抗生素英文課件-Introduction-to-Antibacterial-Therapy_第2頁
抗生素英文課件-Introduction-to-Antibacterial-Therapy_第3頁
抗生素英文課件-Introduction-to-Antibacterial-Therapy_第4頁
抗生素英文課件-Introduction-to-Antibacterial-Therapy_第5頁
已閱讀5頁，還剩75頁未讀， 繼續(xù)免費(fèi)閱讀

下載本文檔

版權(quán)說明：本文檔由用戶提供并上傳，收益歸屬內(nèi)容提供方，若內(nèi)容存在侵權(quán)，請進(jìn)行舉報或認(rèn)領(lǐng)

文檔簡介

IntroductiontoAntibacterialTherapyClinicallyRelevantMicrobiologyandPharmacologyEdwardL.Goodman,MDJuly21,2003IntroductiontoAntibacterial1RationaleAntibioticuse(appropriateornot)leadstomicrobialresistanceResistanceresultsinincreasedmorbidity,mortality,andcostofhealthcareAppropriateantimicrobialstewardshipwillpreventorslowtheemergenceofresistanceamongorganisms(ClinicalInfectiousDiseases1997;25:584-99.)Antibioticsareusedas“drugsoffear”(KuninCMAnnals1973;79:555)Rationale2抗生素英文課件——Introduction-to-Antibacterial-Therapy3AntibioticMisuseSurveysrevealthat:25-33%ofhospitalizedpatientsreceiveantibiotics(ArchInternMed1997;157:1689-1694)22-65%ofantibioticuseinhospitalizedpatientsisinappropriate(InfectionControl1985;6:226-230)AntibioticMisuseSurveysrevea4ConsequencesofMisuseofAntibioticsContagiousRESISTANCENoequivalentdownsidetooveruseofendoscopy,calciumchannelblockers,etc.Morbidity-drugtoxicityMortalityCostConsequencesofMisuseofAnt5Outline

BasicClinicalBacteriologyCategoriesofAntibioticsPharmacologyofAntibioticsOutline

BasicClinicalBacter6Goodman’sSchemefortheMajorClassesofBacterialPathogens

GramPositiveCocciGramNegativeRodsFastidiousGNRAnaerobesGoodman’sSchemefortheMajor7GramPositiveCocciGramstain:clustersCatalasepos=StaphCoagpos=SaureusCoagneg=varietyofspeciesChainsandpairsCatalaseneg=streptococciClassifybyhemolysisTypebyspecificCHOGramPositiveCocciGramstain:8Staphylococcusaureus>95%producepenicillinase(betalactamase)=penicillinresistantAtPHD~50%ofSAarehetero(methicillin)resistant=MRSAGlycopeptide(vancomycin)intermediate(GISA)MIC8-16Eightnationwide(oneatPHD)VRSAreportedJuly5,2002MMWRMIC>128Staphylococcusaureus>95%prod9S.aureusPenicillin[1950s]Penicillin-resistantS.aureusEvolutionofDrugResistanceinS.aureusMethicillin[1970s]Methicillin-resistant

S.aureus(MRSA)Vancomycin-resistantenterococci(VRE)Vancomycin[1990s][1997]Vancomycinintermediate-resistantS.aureus

(VISA)

[2002]Vancomycin-resistantS.aureusS.aureusPenicillin[1950s]Peni10MSSAvs.MRSA

SurgicalSiteInfections

(1994-2000)MSSAvs.MRSA

SurgicalSiteI11CoagulaseNegativeStaphManyspecies–S.epidermidismostcommonMostlymethicillinresistant(65%)Oftencontaminantsorcolonizers–usespecificcriteriatodistinguishMajorcauseofoveruseofvancomycinCoagulaseNegativeStaphManys12NosocomialBloodstreamIsolatesSCOPEProjectOther(11%)Coagulase-negativestaphylococci(32%)Enterococci(11%)Allgram-negative(21%)Candida

(8%)Viridansstreptococci(1%)Staphylococciaureus(16%)ClinInfectDis1999;29:239-244NosocomialBloodstreamIsolate13StreptococciBetahemolysis:GroupA,B,Cetc.Invasive–mimicstaphinvirulenceS.pyogenes(GroupA)Pharyngitis,SofttissueNonsuppurativesequellae:ARF,AGNStreptococciBetahemolysis:Gr14Betastrept-continuedS.agalactiae(GroupB)Peripartum/NeonatalDiabeticfootBacteremia/endocarditis/metastaticfociGroupD(nonenterococcal)=S.bovisAssociatedwithcarcinomaofcolonBetastrept-continuedS.agal15ViridansStreptococciManyspeciesStreptococcusintermediusgroupLiverabscessEndocarditisGIorpharyngealfloraMostotheraremouthflora–causeIEViridansStreptococciManyspec16EnterococciFormerlyconsideredGroupDStreptococci nowaseparategenusBacteremia/EndocarditisBacteriuriaPartofmixedabdominal/pelvicinfectionsIntrinsicallyresistanttocephalosporinsNobactericidalsingleagentEnterococciFormerlyconsidered17GramNegativeRodsFermentorsOxidasenegativeFacultativeanaerobesEntericfloraNumerousgeneraEscherischiaEnterobacterSerratia,etcNon-fermentorsOxidasepositivePureaerobesPseudomonasandAcinetobacterNosocomialOpportunisticInherentlyresistantGramNegativeRodsFermentorsNo18FastidiousGramNegativeRodsNeisseria,Hemophilus,Moraxella,HACEKRequireCO2forgrowthNeisseriamustbeplatedatbedsideChocolateagarwithCO2LigasechainreactionhasreducednumberofculturesforN.gonorrhea

FastidiousGramNegativeRodsN19AnaerobesGramnegativerodsBacteroidesFusobacteriaGrampositiverodsClostridiaProprionobacteriaGrampositivecocciPeptostreptococciandpeptococciAnaerobesGramnegativerods20AnaerobicGramNegativeRodsProducebetalactamaseEndogenousfloraPartofmixedinfectionsConferfoulodorHeterogeneousmorphologyFastidiousAnaerobicGramNegativeRodsPr21AntibioticClassification

accordingtoGoodmanNarrowSpectrumActiveagainstonlyoneofthefourclassesBroadSpectrumActiveagainstmorethanoneoftheclassesBoutiqueActiveagainstaselectnumberwithinaclassAntibioticClassification

acco22NarrowSpectrumActivemostlyagainstonlyoneoftheclassesofbacteriagrampositive:glycopeptides,linezolidaerobicgramnegative:aminoglycosides,aztreonamanaerobes:metronidazoleNarrowSpectrumActivemostlya23NarrowSpectrumGPCGNRFastidAnaerVanc++++----------onlyclostridiaLinezolid++++----------OnlygramposAG-----++++++-----Aztreon-----++++-----Metro---------------++++NarrowSpectrumGPCGNRFastidAna24BroadSpectrum ActiveagainstmorethanoneclassGPCandanaerobes:clindamycinGPCandGNR:cephalosporins,penicillins,T/S,newerFQGPC,GNRandanaerobes:ureidopenicillins±BLI,carbapenemsGPCandfastidious:macrolidesBroadSpectrum Activeagainst25PenicillinsStrepOSSAGNRFastidAnaerPen+++--+/----+/--Amp/amox+++--++/--+/--Ticar++--+++/--+Ureid+++--+++++++++BLI+++++++++++++++++Carba++++++++++++++++++PenicillinsStrepOSSAGNRFastidA26CephalosporinsGPCnon-MRSAGNRFASTIDANAERCeph1+++++----Ceph2+++++--Cepha-mycin++++++++Ceph3+++++++++--Ceph4++++++++++--CephalosporinsGPCnon-MRSAGNR27BoutiqueAntibioticsJustliketheMallspecialtystoresspecialtydrugsOftenliketheMall–storesinsearchofbusiness;drugsinsearchofdiseasesSynercid–forVREfaecium,notfaecalis,MRSALinezolid–VRE,MRSAIDconsultneededBoutiqueAntibioticsJustlike28Pharmacodynamics

MIC=lowestconcentrationtoinhibitgrowthMBC=thelowestconcentrationtokillPeak=highestserumlevelafteradoseAUC=areaundertheconcentrationtimecurvePAE=persistentsuppressionofgrowthfollowingexposuretoantimicrobialPharmacodynamics

MIC=lowestco29ParametersofantibacterialefficacyTimeaboveMIC-betalactams,macrolides,clindamycin,glycopeptides24hourAUC/MIC-aminoglycosides,fluoroquinolones,azalides,tetracyclines,glycopeptides,quinupristin/dalfopristinPeak/MIC-aminoglycosides,fluoroquinolonesParametersofantibacterialef30TimeoverMIC ShouldexceedMICforatleast50%ofdoseintervalHigherdosesmayallowadequatetimeoverMICFormostbetalactams,optimaltimeoverMICcanbeachievedbycontinuousinfusion(exceptunstabledrugssuchasimipenem,ampicillin)TimeoverMIC ShouldexceedMI31HigherSerum/tissuelevelsareassociatedwithfasterkilling AminoglycosidesPeak/MICratioof>10-12optimalAchievedby“OnceDailyDosing”PAEhelpsFluoroquinolones10-12ratioachievedforentericGNRPAEhelpsnotachievedfor

PseudomonasnorStreptococcuspneumoniaeHigherSerum/tissuelevelsare32AUC/MIC=AUICForStreptococcuspneumoniae,FQshouldhaveAUIC>=30ForgramnegativerodswherePeak/MICratioof10-12notpossible,thenAUICshould>=125.AUC/MIC=AUICForStreptococcu33AntibioticUseandResistance-Strongepidemiologicalevidencethatantibioticuseinhumansandanimalsassociatedwithincreasingresistance-Subtherapeuticdosingencouragesresistantmutantstoemerge;conversely,rapidbactericidalactivitydiscourages-HospitalantibioticcontrolprogramshavebeendemonstratedtoreduceresistanceAntibioticUseandResistance-34TotalAntibiotic

Doses/DayTotalAntibiotic

Doses/Day35ChangesinBug/DrugSusceptibilityPatternsChangesinBug/DrugSusceptibi36FurtherActivitiesofCAMPDecreaseinappropriatefluoroquinoloneuseStaffeducationRestrictedreportingDecreaseinappropriatesputumculturesStaffeducationLaboratorydisclaimerDecreaseinappropriatevancomycinlevelsEducationaboutunnecessarypeaklevelsFurtherActivitiesofCAMPDecr37FurtherActivitiesofCAMPMonitorsurgicalsiteinfectionsandinterveneasnecessaryImprovedtimingandadministrationofpre-opantibioticsclippingnotshavingnasaldecolonizationchangingpathogens(MRSA,gram-rods)Automatedprotocol-drivenantibioticprescribingComputerizedphysicianorderentryFurtherActivitiesofCAMPMoni38AntibioticArmageddon“ThereisonlyathinredlineofIDpractitionerswhohavededicatedthemselvestorationaltherapyandcontrolofhospitalinfections”KuninCID1997;25:240AntibioticArmageddon“Thereis39Historicoverviewontreatmentofinfections2000BC:Eatthisroot1000AD:Saythisprayer1800’s:Takethispotion1940’s:Takepenicillin,itisamiracledrug1980’s:Takethisnewantibiotic,itisbetter?2003AD:EatthisrootHistoricoverviewontreatment40IntroductiontoAntibacterialTherapyClinicallyRelevantMicrobiologyandPharmacologyEdwardL.Goodman,MDJuly21,2003IntroductiontoAntibacterial41RationaleAntibioticuse(appropriateornot)leadstomicrobialresistanceResistanceresultsinincreasedmorbidity,mortality,andcostofhealthcareAppropriateantimicrobialstewardshipwillpreventorslowtheemergenceofresistanceamongorganisms(ClinicalInfectiousDiseases1997;25:584-99.)Antibioticsareusedas“drugsoffear”(KuninCMAnnals1973;79:555)Rationale42抗生素英文課件——Introduction-to-Antibacterial-Therapy43AntibioticMisuseSurveysrevealthat:25-33%ofhospitalizedpatientsreceiveantibiotics(ArchInternMed1997;157:1689-1694)22-65%ofantibioticuseinhospitalizedpatientsisinappropriate(InfectionControl1985;6:226-230)AntibioticMisuseSurveysrevea44ConsequencesofMisuseofAntibioticsContagiousRESISTANCENoequivalentdownsidetooveruseofendoscopy,calciumchannelblockers,etc.Morbidity-drugtoxicityMortalityCostConsequencesofMisuseofAnt45Outline

BasicClinicalBacteriologyCategoriesofAntibioticsPharmacologyofAntibioticsOutline

BasicClinicalBacter46Goodman’sSchemefortheMajorClassesofBacterialPathogens

GramPositiveCocciGramNegativeRodsFastidiousGNRAnaerobesGoodman’sSchemefortheMajor47GramPositiveCocciGramstain:clustersCatalasepos=StaphCoagpos=SaureusCoagneg=varietyofspeciesChainsandpairsCatalaseneg=streptococciClassifybyhemolysisTypebyspecificCHOGramPositiveCocciGramstain:48Staphylococcusaureus>95%producepenicillinase(betalactamase)=penicillinresistantAtPHD~50%ofSAarehetero(methicillin)resistant=MRSAGlycopeptide(vancomycin)intermediate(GISA)MIC8-16Eightnationwide(oneatPHD)VRSAreportedJuly5,2002MMWRMIC>128Staphylococcusaureus>95%prod49S.aureusPenicillin[1950s]Penicillin-resistantS.aureusEvolutionofDrugResistanceinS.aureusMethicillin[1970s]Methicillin-resistant

S.aureus(MRSA)Vancomycin-resistantenterococci(VRE)Vancomycin[1990s][1997]Vancomycinintermediate-resistantS.aureus

(VISA)

[2002]Vancomycin-resistantS.aureusS.aureusPenicillin[1950s]Peni50MSSAvs.MRSA

SurgicalSiteInfections

(1994-2000)MSSAvs.MRSA

SurgicalSiteI51CoagulaseNegativeStaphManyspecies–S.epidermidismostcommonMostlymethicillinresistant(65%)Oftencontaminantsorcolonizers–usespecificcriteriatodistinguishMajorcauseofoveruseofvancomycinCoagulaseNegativeStaphManys52NosocomialBloodstreamIsolatesSCOPEProjectOther(11%)Coagulase-negativestaphylococci(32%)Enterococci(11%)Allgram-negative(21%)Candida

(8%)Viridansstreptococci(1%)Staphylococciaureus(16%)ClinInfectDis1999;29:239-244NosocomialBloodstreamIsolate53StreptococciBetahemolysis:GroupA,B,Cetc.Invasive–mimicstaphinvirulenceS.pyogenes(GroupA)Pharyngitis,SofttissueNonsuppurativesequellae:ARF,AGNStreptococciBetahemolysis:Gr54Betastrept-continuedS.agalactiae(GroupB)Peripartum/NeonatalDiabeticfootBacteremia/endocarditis/metastaticfociGroupD(nonenterococcal)=S.bovisAssociatedwithcarcinomaofcolonBetastrept-continuedS.agal55ViridansStreptococciManyspeciesStreptococcusintermediusgroupLiverabscessEndocarditisGIorpharyngealfloraMostotheraremouthflora–causeIEViridansStreptococciManyspec56EnterococciFormerlyconsideredGroupDStreptococci nowaseparategenusBacteremia/EndocarditisBacteriuriaPartofmixedabdominal/pelvicinfectionsIntrinsicallyresistanttocephalosporinsNobactericidalsingleagentEnterococciFormerlyconsidered57GramNegativeRodsFermentorsOxidasenegativeFacultativeanaerobesEntericfloraNumerousgeneraEscherischiaEnterobacterSerratia,etcNon-fermentorsOxidasepositivePureaerobesPseudomonasandAcinetobacterNosocomialOpportunisticInherentlyresistantGramNegativeRodsFermentorsNo58FastidiousGramNegativeRodsNeisseria,Hemophilus,Moraxella,HACEKRequireCO2forgrowthNeisseriamustbeplatedatbedsideChocolateagarwithCO2LigasechainreactionhasreducednumberofculturesforN.gonorrhea

FastidiousGramNegativeRodsN59AnaerobesGramnegativerodsBacteroidesFusobacteriaGrampositiverodsClostridiaProprionobacteriaGrampositivecocciPeptostreptococciandpeptococciAnaerobesGramnegativerods60AnaerobicGramNegativeRodsProducebetalactamaseEndogenousfloraPartofmixedinfectionsConferfoulodorHeterogeneousmorphologyFastidiousAnaerobicGramNegativeRodsPr61AntibioticClassification

accordingtoGoodmanNarrowSpectrumActiveagainstonlyoneofthefourclassesBroadSpectrumActiveagainstmorethanoneoftheclassesBoutiqueActiveagainstaselectnumberwithinaclassAntibioticClassification

acco62NarrowSpectrumActivemostlyagainstonlyoneoftheclassesofbacteriagrampositive:glycopeptides,linezolidaerobicgramnegative:aminoglycosides,aztreonamanaerobes:metronidazoleNarrowSpectrumActivemostlya63NarrowSpectrumGPCGNRFastidAnaerVanc++++----------onlyclostridiaLinezolid++++----------OnlygramposAG-----++++++-----Aztreon-----++++-----Metro---------------++++NarrowSpectrumGPCGNRFastidAna64BroadSpectrum ActiveagainstmorethanoneclassGPCandanaerobes:clindamycinGPCandGNR:cephalosporins,penicillins,T/S,newerFQGPC,GNRandanaerobes:ureidopenicillins±BLI,carbapenemsGPCandfastidious:macrolidesBroadSpectrum Activeagainst65PenicillinsStrepOSSAGNRFastidAnaerPen+++--+/----+/--Amp/amox+++--++/--+/--Ticar++--+++/--+Ureid+++--+++++++++BLI+++++++++++++++++Carba++++++++++++++++++PenicillinsStrepOSSAGNRFastidA66CephalosporinsGPCnon-MRSAGNRFASTIDANAERCeph1+++++----Ceph2+++++--Cepha-mycin++++++++Ceph3+++++++++--Ceph4++++++++++--CephalosporinsGPCnon-MRSAGNR67BoutiqueAntibioticsJustliketheMallspecialtystoresspecialtydrugsOftenliketheMall–storesinsearchofbusiness;drugsinsearchofdiseasesSynercid–forVREfaecium,notfaecalis,MRSALinezolid–VRE,MRSAIDconsultneededBoutiqueAntibioticsJustlike68Pharmacodynamics

MIC=lowestconcentrationtoinhibitgrowthMBC=thelowestconcentrationtokillPeak=highestserumlevelafteradoseAUC=areaundertheconcentrationtimecurvePAE=persistentsuppressionofgrowthfollowingexposuretoantimicrobialPharmacodynamics

MIC=lowestco69ParametersofantibacterialefficacyTimeaboveMIC-betalactams,macrolides,clindamycin,glycopeptides24hourAUC/MIC-aminoglycosides,fluoroquinolones,azalides,tetracyclines,glycopeptides,quinupristin/dalfopristinPeak/MIC-aminoglycosides,fluoroquinolonesParametersofantibacterialef70TimeoverMIC ShouldexceedMICforatleast50%ofdoseintervalHigherdosesmayallowadequatetimeoverMICFormostbetalactams,optimaltimeoverMICcanbeachievedbycontinuousinfusion(exceptunstabledrugssuchasimipenem,ampicillin)TimeoverMIC ShouldexceedMI71HigherSerum/tissuelevelsareassociatedwithfasterkilling AminoglycosidesPeak/MICratioof>10-12optimalAchievedby“OnceDailyDosing”PAEhelpsFluoroquinolones10-12ratioachievedforentericGNRPAEhelpsnotachievedfor

PseudomonasnorStreptococcuspneumoniaeHig

溫馨提示

  • 1. 本站所有資源如無特殊說明，都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等，如果需要附件，請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙，網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽，若沒有圖紙預(yù)覽就沒有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫網(wǎng)僅提供信息存儲空間，僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理，對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯，并不能對任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容，請與我們聯(lián)系，我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。

評論

0/150

提交評論